MIM
FATE icon

Macroview Investment Management’s Fate Therapeutics FATE Stock Holding History

Macroview Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,165
Closed -$10.3K – 820
2023
Q2 		$10.3K Buy
+2,165
New +$11.9K 0.02% 270
2023
Q1 		– Sell
-1,034
Closed -$10.4K – 473
2022
Q4 		$10.4K Buy
+1,034
New +$19.4K 0.02% 243
2020
Q4 		– Sell
-73
Closed -$3K – 357
2020
Q3 		$3K Buy
+73
New +$2.55K 0.01% 209

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Macroview Investment Management's FATE Position: Q3 2023 in Review

Macroview Investment Management sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 2,165 shares — an estimated $10.3K sold.

Macroview Investment Management first reported a position in FATE in Q3 2020 and held it in 3 quarters. The position peaked at $10.4K in Q4 2022. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Macroview Investment Management reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Macroview Investment Management sold 2,165 Fate Therapeutics shares in Q3 2023, an estimated $10.3K.
  • Macroview Investment Management first reported a position in Fate Therapeutics in Q3 2020 and held it in 3 quarters.
  • Macroview Investment Management's Fate Therapeutics position peaked at $10.4K in Q4 2022.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Macroview Investment Management's 13F filing for Q3 2023, filed 26 Oct 2023.